FINWIRES · TerminalLIVE
FINWIRES

CIBC Confirms Outperformer Rating on Cargojet and Raises Target to $125 on Q1 Results

By

-- CIBC Capital Markets maintained its outperformer rating on the shares of Cargojet (CJT.TO) and raised its price target to C$125 from C$122 after the company reported its first-quarter financial results on Monday.

Cargojet "continues to demonstrate its ability to extract incremental value from its existing fleet through improved asset utilisation and flexible redeployment," it said. About 12 to 13 aircraft operated for DHL are now available up to three days per week "for incremental charter opportunities, materially improving aircraft and crew productivity while lowering idle time," the bank noted.

CIBC has seen the company "continue to benefit from healthy domestic demand environment while offsetting shorter-haul ACMI flying with charter opportunities."

"The air freight market continues to face macro turbulence, whether it is ongoing trade uncertainty, the spike in fuel prices, or the Middle East conflict," said analyst Kevin Chiang. "CJT's Q1 results and outlook continue to demonstrate that the company is navigating through these headwinds."

CIBC's 2026 and 2027 EBITDA forecast move to $341 million from $331 million expected earlier and to $355 million from $353 million, respectively, to reflect the company's revenue outlook and the current fuel price environment. Its EPS forecast moves lower as it adjusts its D&A expenses higher, the bank added.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Price: $82.50, Change: $+4.80, Percent Change: +6.18%

Related Articles

Australia

Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says

Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%

$APTV$F
Research

Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target

Price: $15.79, Change: $-4.34, Percent Change: -21.55%

$CRTO
Australia

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%

$OCUL